New bladder cancer drug faces off against standard therapy in phase 2 trial
NCT ID NCT07374549
First seen Jan 31, 2026 · Last updated May 13, 2026 · Updated 17 times
Summary
This study compares a new drug called SYS6002 to the current standard drug PADCEV in people with advanced bladder cancer that has worsened after prior treatments. About 100 adults aged 18-80 will be enrolled to see which drug works better and has fewer side effects. The trial has not started recruiting yet.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.